Skip to content

Innovative Study on the Use of Bupivacaine Liposome Fascia Block for Postoperative Pain Management in Elderly Total Hip Arthroplasty

Innovative Study on the Use of Bupivacaine Liposome Fascia Block for Postoperative Pain Management in Elderly Total Hip Arthroplasty

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116149
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip replacement

Interventions

Low dose group:Before anesthesia induction, administer liposomal bupivacaine for iliac fascia block: liposomal bupivacaine 133 mg with 20 mL of 0.9% saline = 30 mL
High-dose group:Before anesthesia induction, administer a fascia iliaca block with liposomal bupivacaine: Liposomal bupivacaine 266 mg in 10 mL of 0.9% saline = 30 mL
Ropivacaine group:Administer ropivacaine for iliac fascia block before anesthesia induction: 1% ropivacaine 100 mg + 0.9% saline 20 mL = 30 mL

Sponsors

The First Affiliated Hospital of Anhui University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age between 65 and 80 years, no gender restriction; 2. Patients classified as ASA I~III by the American Society of Anesthesiologists; 3. Patients who are informed, voluntarily participate in the clinical trial, and have signed the Informed Consent Form for Clinical Trials; 4. Patients who are able to actively cooperate with medical staff.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cognitive impairment who cannot cooperate with an iliac fascia block; 2. Severe coagulation disorders; 3. History of allergy to local anesthetics; 4. Presence of infection, nerve injury, or other issues at the puncture site; 5. Severe cardiovascular or pulmonary disease; 6. Surgery duration longer than 3 hours.

Design outcomes

Primary

MeasureTime frame
Postoperative resting and movement Numerical Rating Scale (NRS) pain intensity score area under the curve (AUC);

Secondary

MeasureTime frame
Biochemical indicators: C-reactive protein, erythrocyte sedimentation rate, interleukin-6, cortisol, and malondialdehyde;Total consumption of opioids;Number of rescue analgesia doses and time to first rescue analgesia;Postoperative muscle strength recovery: Assessment of quadriceps strength using an electronic dynamometer and the 30-second chair stand test;Bupivacaine levels in the blood samples of patients after iliac fascia block;Monitor and record any adverse events and postoperative complications (opioid-related side effects such as nausea, vomiting, and itching, as well as potential cardiac and neurotoxic side effects);Record the length of hospital stay and the postoperative quality of life and satisfaction of patients;

Countries

China

Contacts

Public ContactLiu Minghong

The First Affiliated Hospital of Anhui University of Science and Technology

18355455137@163.com+86 183 5545 5137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026